{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=4+mL+Injection+of+Placebo&page=6",
    "query": {
      "intervention": "4 mL Injection of Placebo",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 332,
    "total_pages": 34,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=4+mL+Injection+of+Placebo&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=4+mL+Injection+of+Placebo&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T11:15:12.819Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00376935",
      "title": "Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Palifermin",
          "type": "DRUG"
        },
        {
          "name": "Palifermin placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 99,
      "start_date": "2006-12",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-10-17T11:15:12.819Z",
      "location_count": 22,
      "location_summary": "Los Angeles, California • Palo Alto, California • San Diego, California + 15 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00376935"
    },
    {
      "nct_id": "NCT00694733",
      "title": "Regulation of Cortisol Metabolism and Fat Patterning",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity",
        "Menopausal Syndrome"
      ],
      "interventions": [
        {
          "name": "Placebo injection",
          "type": "DRUG"
        },
        {
          "name": "Depo Lupron/Aromatase inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Depo Lupron/placebo",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "Estrogen cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "62 Years",
        "sex": "ALL",
        "summary": "18 Years to 62 Years"
      },
      "enrollment_count": 140,
      "start_date": "2005-05",
      "completion_date": "2024-09",
      "has_results": false,
      "last_update_posted_date": "2022-12-16",
      "last_synced_at": "2026-10-17T11:15:12.819Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00694733"
    },
    {
      "nct_id": "NCT00546585",
      "title": "Safety, Reactogenicity, and Immunogenicity of Inactivated Influenza A/H7/N7 Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Influenza A/H7N7 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 126,
      "start_date": "2008-03",
      "completion_date": "2009-02",
      "has_results": false,
      "last_update_posted_date": "2013-08-23",
      "last_synced_at": "2026-10-17T11:15:12.819Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00546585"
    },
    {
      "nct_id": "NCT04177355",
      "title": "Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "BG505 SOSIP.664 gp140",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "3M-052-AF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CpG 1018",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GLA-LSQ",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Alum (Aluminum Hydroxide Suspension)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trimer 4571",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 127,
      "start_date": "2020-01-13",
      "completion_date": "2024-11-04",
      "has_results": true,
      "last_update_posted_date": "2025-09-02",
      "last_synced_at": "2026-10-17T11:15:12.819Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Decatur, Georgia + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04177355"
    },
    {
      "nct_id": "NCT06007183",
      "title": "Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster Vaccination",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chikungunya Virus Infection"
      ],
      "interventions": [
        {
          "name": "CHIKV VLP vaccine booster",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo booster",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bavarian Nordic",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 715,
      "start_date": "2023-08-30",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2026-08-07",
      "last_synced_at": "2026-10-17T11:15:12.819Z",
      "location_count": 24,
      "location_summary": "Mobile, Alabama • Tempe, Arizona • Melbourne, Florida + 20 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06007183"
    },
    {
      "nct_id": "NCT00500747",
      "title": "Chiron Corp HCV E1/E2 Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "HCV E1E2/MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 60,
      "start_date": "2003-08",
      "completion_date": "2005-08",
      "has_results": false,
      "last_update_posted_date": "2011-06-10",
      "last_synced_at": "2026-10-17T11:15:12.819Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00500747"
    },
    {
      "nct_id": "NCT05875948",
      "title": "Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatorenal Syndrome",
        "Acute Kidney Injury"
      ],
      "interventions": [
        {
          "name": "R2R01",
          "type": "DRUG"
        },
        {
          "name": "Terlipressin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "River 2 Renal Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 95,
      "start_date": "2023-06-30",
      "completion_date": "2024-12",
      "has_results": false,
      "last_update_posted_date": "2023-10-03",
      "last_synced_at": "2026-10-17T11:15:12.819Z",
      "location_count": 7,
      "location_summary": "San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05875948"
    },
    {
      "nct_id": "NCT04926818",
      "title": "Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis (MS)"
      ],
      "interventions": [
        {
          "name": "Fingolimod",
          "type": "DRUG"
        },
        {
          "name": "Ofatumumab",
          "type": "DRUG"
        },
        {
          "name": "Siponimod",
          "type": "DRUG"
        },
        {
          "name": "Fingolimod placebo",
          "type": "OTHER"
        },
        {
          "name": "Siponimod placebo",
          "type": "OTHER"
        },
        {
          "name": "Ofatumumab placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 129,
      "start_date": "2021-10-05",
      "completion_date": "2031-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-05-14",
      "last_synced_at": "2026-10-17T11:15:12.819Z",
      "location_count": 6,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 3 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04926818"
    },
    {
      "nct_id": "NCT05004727",
      "title": "Multi-Center PAMPA Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Guselkumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 176,
      "start_date": "2022-02-16",
      "completion_date": "2028-11-02",
      "has_results": false,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-10-17T11:15:12.819Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • New York, New York • Rochester, New York",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05004727"
    },
    {
      "nct_id": "NCT02760407",
      "title": "Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Olokizumab 64mg q4w",
          "type": "DRUG"
        },
        {
          "name": "Olokizumab 64mg q2w",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab 40mg q2w",
          "type": "DRUG"
        },
        {
          "name": "Placebo q2w",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "R-Pharm International, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1648,
      "start_date": "2016-06-06",
      "completion_date": "2019-11-05",
      "has_results": true,
      "last_update_posted_date": "2023-09-21",
      "last_synced_at": "2026-10-17T11:15:12.819Z",
      "location_count": 64,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 55 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Covina",
          "state": "California"
        },
        {
          "city": "El Cajon",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02760407"
    }
  ]
}